Stock ANL ADLAI NORTYE LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Adlai Nortye Ltd.

Equities

ANL

US00704R1095

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:30:00 27/06/2024 BST 		5-day change 1st Jan Change
3.71 USD +6.45% Intraday chart for Adlai Nortye Ltd. +2.76% -58.73%
05-24 Adlai Nortye Ltd. Announces to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy At ASCO 2024 CI
05-22 Adlai Nortye Announces First Patient Dosed in Randomized Phase Ii Clinical Trial of Palupiprant for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy CI

Valuation

Fiscal Period: December 2023 2024 2025 2026
Capitalization 1 331.7 128.6 - -
Enterprise Value (EV) 1 331.7 128.6 128.6 128.6
P/E ratio - - - -
Yield - - - -
Capitalization / Revenue 54.4 x - - 0.38 x
EV / Revenue 54.4 x - - 0.38 x
EV / EBITDA - - - -
EV / FCF - - -1,082,470 x 1,837,106 x
FCF Yield - - -0% 0%
Price to Book - - - -
Nbr of stocks (in thousands) 36,900 36,900 - -
Reference price 2 8.990 3.710 3.710 3.710
Announcement Date 19/04/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 - 6.098 - - 335.4
EBITDA - - - - -
EBIT 1 - -10.54 -91.5 -150 88.9
Operating Margin - -172.92% - - 26.51%
Earnings before Tax (EBT) - - - - -
Net income -58.79 - - - -
Net margin - - - - -
EPS -2.310 - - - -
Free Cash Flow - - - -118.8 70
FCF margin - - - - 20.87%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 27/07/23 19/04/24 - - -
1USD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2 2025 Q1
Net sales 1 - - - - - - -
EBITDA - - - - - - -
EBIT - - - - - - -
Operating Margin - - - - - - -
Earnings before Tax (EBT) - - - - - - -
Net income - - - - - - -
Net margin - - - - - - -
EPS - - - - - - -
Dividend per Share - - - - - - -
Announcement Date - - - - - - -
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - -119 70
ROE (net income / shareholders' equity) - - - - -
ROA (Net income/ Total Assets) - - - - -
Assets - - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex 1 - - 2.5 2.5 2.5
Capex / Sales - - - - 0.75%
Announcement Date 27/07/23 19/04/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.485
Average target price
-
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ADLAI NORTYE LTD. Stock Adlai Nortye Ltd.
-58.73% 129M
MODERNA, INC. Stock Moderna, Inc.
+21.85% 46.93B
LONZA GROUP AG Stock Lonza Group AG
+37.63% 39.08B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.05% 38.48B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+29.04% 31.01B
CELLTRION, INC. Stock Celltrion, Inc.
-13.75% 26.14B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.65% 25.88B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+38.43% 12.53B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-6.92% 11.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-12.29% 10.65B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ANL Stock
  4. Financials Adlai Nortye Ltd.